GlassScriptPhysician profile
Frank Mcgrew
NPI 1922190396
$119,175.62
in general payments reported to CMS, 2019-2025
65 companies · $13K in 2025
The $13K reported for 2025 was more than what 95% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $38K · 2020: $8,172 · 2021: $8,532 · 2022: $19K · 2023: $17K · 2024: $14K · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Consulting Fee: $14K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K · Travel and Lodging: $3,297 · Education: $107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,425.69 |
| Consulting Fee | $14,410.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,514.00 |
| Travel and Lodging | $3,297.45 |
| Education | $107.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $23,772.30 | 2019-2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $17,475.60 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $12,341.04 | 2019-2025 | Wainua, Farxiga, Brilinta |
| Bayer Healthcare Pharmaceuticals INC. | $11,734.06 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $8,759.31 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $8,053.87 | 2019-2025 | Zepbound |
| Janssen Pharmaceuticals, INC | $7,934.71 | 2019-2024 | Xarelto |
| Medtronic, INC. | $5,958.62 | 2021-2025 | Micra, Aurora Ev-Icd Mri Surescan, Cobalt Dr Mri Surescan |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $4,463.12 | 2019-2025 | Lifevest |
| Pfizer INC. | $3,324.62 | 2019-2024 | |
| Amgen INC. | $2,414.00 | 2019-2025 | Repatha, Repatha |
| Alnylam Pharmaceuticals INC. | $1,434.15 | 2022-2025 | Amvuttra, Onpattro |
| Abbott Laboratories | $1,287.11 | 2019-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit, Aveir |
| Altathera Pharmaceuticals LLC | $1,123.98 | 2022-2024 | Sotalol Hydrochloride |
| Merck Sharp & Dohme LLC | $1,024.94 | 2019-2025 | Verquvo, Winrevair |
Show all 57 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $883.39 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Actelion Pharmaceuticals US, INC. | $786.54 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Impulse Dynamics (USA) INC. | $767.53 | 2022-2025 | Optimizer, Optimizer |
| Medtronic Vascular, INC. | $641.94 | 2019-2020 | |
| Cvrx, INC. | $610.37 | 2021-2025 | Barostim Neo System |
| Celgene Corporation | $600.00 | 2022 | |
| Sanofi-Aventis U.S. LLC | $332.75 | 2019-2024 | |
| Amarin Pharma, INC. | $332.70 | 2019-2023 | |
| Boston Scientific Corporation | $325.96 | 2019-2025 | S-Icd System Magnet, Cds - Mct/Cem Monitoring |
| Zoll Circulation INC | $286.96 | 2024 | Catheter, Therox Ds2 Console, Downstream Cartridge |
| Biotronik INC. | $213.30 | 2019-2025 | Solia, Biomonitor, Acticor 7 Vr-T Dx |
| Esperion Therapeutics, INC. | $184.07 | 2021-2024 | Nexletol |
| Regeneron Healthcare Solutions, INC. | $170.02 | 2019 | |
| Lundbeck LLC | $157.14 | 2019-2020 | |
| Daxor Corporation | $154.26 | 2024 | Bva-100 |
| Comsort, INC | $150.00 | 2019 | |
| Zoll Respicardia, INC. | $142.84 | 2022 | |
| Atricure, INC. | $135.31 | 2025 | Epi-Ease Epicardial Access System |
| Itamar Medical INC | $129.74 | 2022-2024 | Watchpatone |
| Bridgebio Pharma, INC. | $114.13 | 2025 | Attruby |
| Arbor Pharmaceuticals, INC. | $86.52 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $79.24 | 2019-2022 | |
| Lexicon Pharmaceuticals, INC. | $75.67 | 2023-2024 | Inpefa |
| Heartflow, INC. | $75.26 | 2023-2025 | Ffrct |
| Inspire Medical Systems, INC. | $68.97 | 2024-2025 | Inspire |
| Vivaquant INC, Dba Rhythm Express | $56.97 | 2025 | Rhythm Express |
| United Therapeutics Corporation | $56.26 | 2020-2023 | Tyvaso |
| Scpharmaceuticals INC. | $54.20 | 2023-2025 | |
| Philips North America LLC | $50.52 | 2019-2022 | |
| Astellas Pharma US INC | $49.36 | 2025 | Veozah |
| Daiichi Sankyo INC. | $43.83 | 2025 | Injectafer |
| Portola Pharmaceuticals, LLC | $39.90 | 2019 | |
| Vifor Pharma, INC. | $36.80 | 2019 | |
| Nuwellis, INC. | $28.51 | 2020 | |
| Kiniksa Pharmaceuticals, LTD. | $26.84 | 2023 | Arcalyst |
| Xeris Pharmaceuticals, INC. | $23.94 | 2025 | Recorlev |
| Ironwood Pharmaceuticals, INC | $22.28 | 2023 | Linzess |
| Akcea Therapeutics, INC. | $18.23 | 2019 | |
| Medicure Pharma INC. | $17.10 | 2023 | Zypitamag |
| Artivion, INC. | $16.79 | 2019 | |
| Bardy Diagnostics, INC. | $15.00 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $13.05 | 2019 |
8 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Mcgrew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.